Skip to Navigation
Skip to Main Content
Skip to Related Content

Advertisement

U.S. markets closed

S&P Futures
6,003.00
-0.75(-0.01%)
Dow Futures
43,900.00
-10.00(-0.02%)
Nasdaq Futures
21,230.00
+5.25(+0.02%)
Russell 2000 Futures
2,397.10
+1.40(+0.06%)
Crude Oil
71.77
-0.59(-0.82%)
Gold
2,701.70
-4.10(-0.15%)

Sangamo Therapeutics, Inc. (SGMO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Follow

Visitors trend2W10W9M

2.8100

+0.3400

(+13.77%)

At close: 04:00PM EST

2.8300

+0.02

(+0.71%)

After hours:

07:59PM EST

Trade prices are not sourced from all markets

Previous Close	2.4700
Open	2.4600
Bid	2.7800 x 7600
Ask	2.8400 x 3400
Day's Range	2.4400 - 2.9700
52 Week Range	0.2900 - 2.9700
Volume	15,307,822
Avg. Volume	7,041,322

Market Cap	585.101M
Beta (5Y Monthly)	1.10
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

News

Simply Wall St.
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week
Key Insights The considerable ownership by individual investors in Sangamo Therapeutics indicates that they...
BioPharma Dive
Merck acquires cancer drug startup; Elevidys ex-US sales rise
Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market for its Fabry gene therapy.